These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31612387)

  • 1. Tamsulosin Monotherapy Is Effective in Reducing Ureteral Stent-related Symptoms: A Meta-analysis of Randomized Controlled Studies.
    Chen YB; Gao L; Jiang Q; Ran K; Luo RT
    Curr Med Sci; 2019 Oct; 39(5):707-718. PubMed ID: 31612387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis.
    Wang J; Zhang X; Zhang T; Mu J; Bai B; Lei Y
    World J Urol; 2017 Nov; 35(11):1669-1680. PubMed ID: 28550362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms-outcomes from a network meta-analysis.
    Jian Z; Chen Y; Liu Q; Liao B; Yang T; Li H; Wang K
    World J Urol; 2019 Feb; 37(2):289-297. PubMed ID: 30030658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms.
    El-Nahas AR; Tharwat M; Elsaadany M; Mosbah A; Gaballah MA
    World J Urol; 2016 Jul; 34(7):963-8. PubMed ID: 26453222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin/solifenacin combination: A randomized controlled trial.
    Sahin A; Yildirim C; Yuksel OH; Urkmez A
    Arch Esp Urol; 2020 Jan; 73(1):54-59. PubMed ID: 31950924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
    Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
    Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis.
    Li MC; Wang ZY; Yang J; Guo XL; Wang T; Wang SG; Liu JH; Ye ZQ
    Asian J Androl; 2015; 17(1):124-34. PubMed ID: 25337836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy only shows short-term superiority over monotherapy on ureteral stent-related symptoms - outcome from a randomized controlled trial.
    Liu Q; Liao B; Zhang R; Jin T; Zhou L; Luo D; Liu J; Li H; Wang K
    BMC Urol; 2016 Nov; 16(1):66. PubMed ID: 27846839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2 × 2 factorial randomized trial.
    Park J; Yoo C; Han DH; Shin DW
    World J Urol; 2015 Nov; 33(11):1833-40. PubMed ID: 25809877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of stent related symptoms in patients taking mirabegron, solifenacin, or tamsulosin: A double blinded randomized clinical trial.
    Chandna A; Kumar S; Parmar KM; Sharma AP; Devana SK; Mete UK; Singh SK
    Urologia; 2022 Nov; 89(4):589-596. PubMed ID: 34596484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis.
    Gong M; Dong W; Huang G; Gong Z; Deng D; Qiu S; Yuan R
    Curr Med Res Opin; 2015; 31(9):1781-92. PubMed ID: 26211817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does tamsulosin or mirabegron improve ureteral stent-related symptoms? A prospective placebo-controlled study.
    Yavuz A; Kilinc MF; Aydin M; Ofluoglu Y; Bayar G
    Low Urin Tract Symptoms; 2021 Jan; 13(1):17-21. PubMed ID: 32408390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Combination Therapy with Tamsulosin and Tolterodine Improve Ureteral Stent Discomfort Compared with Tamsulosin Alone? A Double-Blind, Randomized, Controlled Trial.
    Sivalingam S; Streeper NM; Sehgal PD; Sninsky BC; Best SL; Nakada SY
    J Urol; 2016 Feb; 195(2):385-90. PubMed ID: 26393904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Tamsulosin, Oxybutynin, and their combination in the control of double-j stent-related lower urinary tract symptoms.
    Maldonado-Avila M; Garduno-Arteaga L; Jungfermann-Guzman R; Manzanilla-Garcia HA; Rosas-Nava E; Procuna-Hernandez N; Vela-Mollinedo A; Almazan-Trevino L; Guzman-Esquivel J
    Int Braz J Urol; 2016; 42(3):487-93. PubMed ID: 27286111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamsulosin, Solifenacin, and Their Combination for the Treatment of Stent-Related Symptoms: A Randomized Controlled Study.
    Dellis AE; Papatsoris AG; Keeley FX; Bamias A; Deliveliotis C; Skolarikos AA
    J Endourol; 2017 Jan; 31(1):100-109. PubMed ID: 27809592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of pregabalin in relieving ureteral stent-related symptoms: a randomized controlled clinical trial.
    Ragab M; Soliman MG; Tawfik A; Abdel Raheem A; El-Tatawy H; Abo Farha M; Magdy M; Elashry O
    Int Urol Nephrol; 2017 Jun; 49(6):961-966. PubMed ID: 28260223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.
    Drake MJ; Sokol R; Coyne K; Hakimi Z; Nazir J; Dorey J; Klaver M; Traudtner K; Odeyemi IA; Oelke M; van Kerrebroeck P;
    BJU Int; 2016 Jan; 117(1):165-72. PubMed ID: 25907003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Nazir J; Heemstra L; van Engen A; Hakimi Z; Ivanescu C
    BMC Urol; 2015 May; 15():41. PubMed ID: 25956727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.